These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26318748)

  • 1. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients.
    Liang S; Aiqun M; Jiwu L; Ping Z
    Immunol Res; 2016 Apr; 64(2):424-30. PubMed ID: 26318748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR3 and TLR4 as potential clinically biomarkers of cardiovascular risk in coronary artery disease (CAD) patients.
    Shao L; Zhang P; Zhang Y; Lu Q; Ma A
    Heart Vessels; 2014 Sep; 29(5):690-8. PubMed ID: 24146036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory unbalance of TLR3 and TLR4 in PCI patients with or without type 2 diabetes mellitus.
    Shao L; Zhang P; Zhang Y; Ma A
    Immunol Lett; 2014 Sep; 161(1):81-8. PubMed ID: 24845156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant in-stent restenosis in the drug eluting stent era.
    Theodoropoulos K; Mennuni MG; Dangas GD; Meelu OA; Bansilal S; Baber U; Sartori S; Kovacic JC; Moreno PR; Sharma SK; Mehran R; Kini AS
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):777-785. PubMed ID: 27184223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.
    Ganesh SK; Skelding KA; Mehta L; O'Neill K; Joo J; Zheng G; Goldstein J; Simari R; Billings E; Geller NL; Holmes D; O'Neill WW; Nabel EG
    Pharmacogenomics; 2004 Oct; 5(7):952-1004. PubMed ID: 15469413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic patterns of restenosis after percutaneous intervention of chronic total occlusive lesions with drug-eluting stents.
    Lee SP; Shin DH; Park KW; Kang HJ; Koo BK; Cho YS; Yeon TJ; Chae IH; Choi DJ; Kim HS
    Int J Cardiol; 2012 Apr; 156(2):180-5. PubMed ID: 21109317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
    Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
    Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study.
    Habara M; Terashima M; Nasu K; Kaneda H; Yokota D; Ito T; Kurita T; Teramoto T; Kimura M; Kinoshita Y; Tsuchikane E; Asakura Y; Suzuki T
    Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):276-84. PubMed ID: 22945378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era.
    Lee MS; Pessegueiro A; Zimmer R; Jurewitz D; Tobis J
    J Invasive Cardiol; 2008 Aug; 20(8):401-3. PubMed ID: 18688064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents.
    Lee MS; Yang T; Mahmud E; Park KW; Kim HS; Kim MH; Dangas G; Hermiller J; Krucoff M; Rutledge D
    J Invasive Cardiol; 2014 Sep; 26(9):420-6. PubMed ID: 25198484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increment of HFABP Level in Coronary Artery In-Stent Restenosis Segments in Diabetic and Nondiabetic Minipigs: HFABP Overexpression Promotes Multiple Pathway-Related Inflammation, Growth and Migration in Human Vascular Smooth Muscle Cells.
    Chen K; Chen QJ; Wang LJ; Liu ZH; Zhang Q; Yang K; Wang HB; Yan XX; Zhu ZB; Du R; Zhang RY; Shen WF; Lu L
    J Vasc Res; 2016; 53(1-2):27-38. PubMed ID: 27372431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma.
    Sheyhidin I; Nabi G; Hasim A; Zhang RP; Ainiwaer J; Ma H; Wang H
    World J Gastroenterol; 2011 Aug; 17(32):3745-51. PubMed ID: 21990957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.